BioSpace News Archive

Increasing prevalence of chronic diseases, risk of high BP in elderly population, and growing awareness about early diagnosis are some key factors expected to drive global market growth

Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) has been informed by medac, a strategic partner of Medexus, that medac received acknowledgement of receipt from the U.S. Food and Drug Administration (FDA) of the New Drug Application resubmission for Treosulfan (NDA) submitted on April 21, 2022, together with a request to submit information in order to complete medac’s NDA resubmission and initiate FDA review.

Castle Biosciences, Inc. (Nasdaq: CSTL), today announced new study data demonstrating the ability of its TissueCypher® Barrett’s Esophagus test to independently predict malignant progression to high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC) in patients with non-dysplastic (ND), indefinite or low-grade dysplasia (LGD) Barrett’s esophagus (BE).

Rising prevalence of chronic diseases and increasing investments in development of advanced technologies are driving market revenue growth

Continuous advances in medical technology and growing need for advanced physiological models are among the major factors boosting the global Organs-on-Chips (OOCs) market revenue growth.

Increasing prevalence of atrial fibrillation, advancements in AFib prediction and management, and improved precision in diagnosis of this condition are some key factors expected to drive market growth

Increasing elderly population globally, rising incidence of oral diseases among adults and children, and increasing focus on developing affordable dental implants are key factors fueling global market growth

Rapidly growing oil and petroleum and food and beverages sectors, and increasing applications of 2D chromatography are some key factors expected to drive global 2D Chromatography market revenue growth.

Increase in global diabetes population and rise in awareness about diabetes preventive care are key factors driving market revenue growth

Abbott (NYSE: ABT) today announced that the U.S. District Court for the Western District of Michigan has amended the recent consent decree allowing Abbott to release limited quantities of its EleCare® specialty amino acid-based formulas that were previously on hold following the Feb. 17 recall of some powder infant formulas from its Sturgis, Mich., facility.